Clinical trial · Interventional
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
Phase I Study Of The Combination Of 17-AAG And Imatinib Mesylate (Gleevec) In Patients With Blastic Phase, Accelerated Phase Of Chronic Mesylate Leukemia (CML) Or Patients With Chronic Phase CML Who Have Not Achieved A Cytogenetic Response With Imatinib Mesylate
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as 17-N-allylamino-17-demethoxygeldanamycin use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate with chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin when given together with imatinib mesylate in treating patients with chronic myelogenous leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| imatinib mesylate | Drug | Imatinib Mesylate | ALIAS |
| tanespimycin | Drug | Tanespimycin | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of chronic myelogenous leukemia, including any of the following phases:
* Blastic phase
* Greater than 30% blasts in the peripheral blood or bone marrow
* Previously untreated disease OR refractory to or relapsed after most recent therapy
* Accelerated phase, defined by 1 of the following:
* At least 15, but less than 30%, blasts in the peripheral blood or bone marrow
* At least 30% blasts and promyelocytes in the peripheral blood or bone marrow
* Greater than 20% peripheral blood basophilia
* Chronic phase
* No major cytogenetic response (less than 65% Philadelphia chromosome negative) after 12 months of prior imatinib mesylate therapy
* Philadelphia chromosome positive by routine cytogenetics
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* ECOG 0-2
Life expectancy
* At least 3 months
Hematopoietic
* Not specified
Hepatic
* Bilirubin no greater than 1.5 mg/dL
* ALT and AST no greater than 2.5 times upper limit of normal
Renal
* Creatinine less than 1.5 mg/dL
Cardiovascular
* No symptomatic congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia
Other
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No known allergy to eggs
* Able to swallow pills
* No ongoing or active infection
* No psychiatric illness or social situation that would preclude study compliance
* No other concurrent uncontrolled medical illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
* No prior stem cell transplantation
Chemotherapy
* More than 4 weeks since prior chemotherapy (except hydroxyurea or anagrelide) (at least 6 weeks for nitrosoureas or mitomycin)
Endocrine therapy
* Not specified
Radiotherapy
* More than 4 weeks since prior radiotherapy
Surgery
* No prior liver, kidney, or lung transplantation
* More than 14 days since prior major surgery (e.g., thoracotomy or intra-abdominal surgery)
Other
* Prior imatinib mesylate administered within the past 4 weeks is allowed
* No concurrent tacrolimus or cyclosporine as immunosuppressive agents
* No other concurrent investigational agents
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No concurrent agents that alter CYP3A4 activity, including any of the following:
* Grapefruit juice
* Ketoconazole
* Fluconazole
* Itraconazole
* Erythromycin
* Clarithromycin
* Cimetidine
* Terfenadine
* Astemizole
* HIV protease inhibitors (e.g., indinavir and nelfinavir)References
Publications (0)
Data not yet available